Why the study?
To illustrate the location and components of sympathetic nerves in the pulmonary artery, along with different methods and effects of pulmonary artery denervation.
Does pulmonary artery denervation improve hemodynamics and palliate symptoms in patients with pulmonary arterial hypertension?
Does pulmonary artery denervation improve hemodynamics and palliate symptoms in patients with pulmonary arterial hypertension?
Pulmonary artery denervation is a promising therapeutic approach for reducing pulmonary arterial pressure and improving hemodynamics in patients with medication-refractory pulmonary arterial hypertension.
May support PADN for refractory PAH symptoms; leaves open need for randomized trials before practice change.
Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by increased pulmonary arterial pressure and pulmonary arterioles remodeling. Some studies have discovered the relationship between sympathetic nerves (SNs) and pathogenesis of PAH. This review is aimed to illustrate the location and components of SNs in the pulmonary artery, along with different methods and effects of pulmonary artery denervation (PADN). Studies have shown that the SNs distributed mainly around the main pulmonary artery and pulmonary artery bifurcation. And the SNs could be destroyed by three ways: the chemical way, the surgical way and the catheter-based way. PADN can significantly decrease pulmonary arterial pressure rapidly, improve hemodynamic varieties, and then palliate PAH. PADN has been recognized as a prospective and effective therapy for PAH patients, especially for those with medication-refractory PAH. However, further enlarged clinical studies are needed to confirm accurate distribution of SNs in the pulmonary artery and the efficacy of PADN.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: